ClearCell FX1 System

Biolidics in partnership to expand into China cancer diagnostics market

SINGAPORE (June 25): Medical technology company Biolidics has entered into a partnership with Zhongshan TopGene Medical Laboratory Co to develop and commercialise laboratory-developed tests (LDTs) in the field of circulating tumour cells (CTCs) using Biolidics' ClearCell FX1 System and CTChip FR1 biochip.

Certified and licensed to undertake clinical trials in China, Zhongshan TopGene is a wholly-owned subsidiary of TopGene Tech (Guangzhou) Co which specialises in the diagnosis and treatment of cancer in the country.

Biolidics selling 27.5 mil new shares at 28 cents each in conjunction with Catalist listing

SINGAPORE (Dec 11): Medtech company Biolidics is selling 27.5 million new shares at 28 cents each to retail and institutional investors in a private placement ahead of its listing on the Catalist Board of the Singapore Exchange.

See: Clearbridge Health associate Biolidics lodges prelim prospectus

Clearbridge Health associate Biolidics lodges prelim prospectus

SINGAPORE (Nov 26): Biolidics, a cancer diagnostic solutions developer and an associate company of Clearbridge Health, on Friday lodged a preliminary prospectus for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board.

Biolidics, incorporated as Clearbridge Biomedics in 2009, specialises in developing cell enrichment systems that can be combined with other analytical tests for cancer diagnosis, prognosis and treatment selection and monitoring.

Be informed of the stories that matter

Subscribe

Be informed of the stories that matter